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Summary
Vascular endothelial growth factor (VEGF) is central
to the survival and development of the vascular and
nervous systems. We screened phage display librar-
ies and built a peptide-based ligand-receptor map of
binding sites within the VEGF family. We then vali-
dated a cyclic peptide, CPQPRPLC, as a VEGF-mimic
that binds specifically to neuropilin-1 and VEGF re-
ceptor-1. Here, we use NMR spectroscopy to under-
stand the structural basis of the interaction between
our mimic peptide and the VEGF receptors. We show
that: (1) CPQPRPLC has multiple interactive confor-
mations; (2) receptor binding is mediated by the motif
Arg-Pro-Leu; and (3) the Pro residue within Arg-Pro-
Leu participates in binding to neuropilin-1 but not to
VEGF receptor-1, perhaps representing an evolution-
ary gain-of-function. Therefore, Arg-Pro-Leu is a differ-
ential ligand motif to VEGF receptors and a candidate
peptidomimetic lead for VEGF pathway modulation.
Introduction
Vascular endothelial growth factor (VEGF) and its family
members are key molecules in blood vessel formation
[1–4]. These growth factors bind to two families of cell
surface receptors: the tyrosine kinase receptors
(VEGFR-1, VEGFR-2, and VEGFR-3) and the neuropilins
(NRP-1 and NRP-2). VEGFR-1—a high-affinity receptor
for VEGF, placental growth factor (PlGF), and VEGF-
B—is essential for blood vessel formation [5], but its
full biological role is still not entirely clear (reviewed in
[4]). VEGFR-1 participates in tissue revascularization
[6], receptor cross-activation [7], and monocyte-medi-
ated arteriogenesis [8]. On the other hand, NRP-1 was
first identified as a plexin/semaphorin receptor involved
in neuron axon guidance, but was later shown to also be
*Correspondence: warap@mdanderson.org (W.A.), falmeida@
cnrmn.bioqmed.ufrj.br (F.C.L.A.), rpasqual@mdanderson.org (R.P.)
4These authors contributed equally to this work.a VEGF receptor; NRP-1 binds VEGF-B and PlGF, and
has an essential role in blood vessel formation [9, 10].
Some of the similarities between the vascular and ner-
vous systems (i.e., branched, ramified networks) are
not merely coincidental, because they appear to share
molecular mechanisms for differentiation and pattern-
ing formation [11–13]. Recently, it became clear that
VEGF and its receptors are essential not only for blood
vessel formation but also in the nervous system [14, 15].
In fact, VEGF is a pleiotropic growth factor with func-
tions such as neuroprotection, learning and memory,
glial proliferation, and even neurogenesis itself [15, 16].
In previous work, we selected and isolated a cyclic
peptide (sequence CPQPRPLC) from a phage display
random peptide library on VEGF-stimulated endothelial
cells; we also validated CPQPRPLC as a VEGF recep-
tor-ligand specifically targeting VEGFR-1 and NRP-1
[17]. CPQPRPLC contains two overlapping binding mo-
tifs [18]: PRPLC (an NRP-1 binding site within VEGF-
B167) and PQPR (embedded within a 12-residue NRP-1
binding site within VEGF-B186). Thus, in essence,
CPQPRPLC is a chimera between overlapping binding
sites in different VEGF-B isoforms. Of note, we observed
marked differences in the relative inhibitory effect (con-
centration producing half-maximum inhibition of effect
[IC50]) when the synthetic peptide CPQPRPLC was
used to compete for phage binding to either VEGF re-
ceptor [17]. Therefore, while the molecular basis for the
binding remains elusive, we reasoned that CPQPRPLC
interacts with its corresponding VEGF receptors differ-
entially. Here, we use nuclear magnetic resonance
(NMR) spectroscopy-based screening methodology to
elucidate the structural requirements for binding of
CPQPRPLC to VEGFR-1 and to NRP-1. We show that
the differential binding of CPQPRPLC to both VEGF re-
ceptors relies on residues within the motif Arg-Pro-Leu
(RPL); this tripeptide may prove useful as a lead for the
design and development of drugs that modulate VEGF
pathways.
Results
The VEGF-like Peptide CPQPRPLC Has Multiple
Conformations
To study the interaction of CPQPRPLC with its corre-
sponding VEGF receptors, we first set out to under-
stand the behavior of the synthetic peptide in solution.
For an exclusive peptide conformation, only eight reso-
nance lines would be expected in the amide region of
a one-dimensional proton NMR spectrum (1D-1H-
NMR): five amide backbones, two Gln side chains, and
one Arg side chain. Instead, NMR spectrum analysis
of CPQPRPLC revealed 16 resonances at 45ºC, 14 res-
onances at 25ºC, and 12 resonances at 0ºC, indicating
the presence of multiple peptide conformations in aque-
ous solution (Figure 1). Proline trans-isomers seemed to
be favored at lower temperatures and, indeed, the resi-
due Pro4 was found only in trans-conformation below
5ºC. While virtually all residues showed multiple con-
formers, the highest degree of structural variability
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1076Figure 1. The Synthetic Peptide CPQPRPLC
Has Multiple Conformers
One-dimensional 1H-NMR spectra of the
synthetic peptide (amide region) performed
at decreasing temperatures are shown.
Peaks are color-coded. Circles represent
amide resonances and squares represent
side-chain resonances.was found within the Leu7-Cys8-Cys1-Pro2 region,
likely induced by trans-isomerization of the disulfide
bond, Pro residues, or both. Although such conforma-
tional variability tended to decrease toward lower
temperatures, ultimately, a unique lowest-energy con-
former was not observed (Figure 1). Conformational var-
iability of the CPQPRPLC peptide persisted in other
nonaqueous organic solvents, such as dimethylsulfox-
ide (DMSO) or trifluorethanol (TFE).
The Arginine and Leucine Residues of CPQPRPLC
Mediate Binding of the Peptide Conformers to VEGF
Receptors
The conformational variability displayed by the peptide
notwithstanding, we sought to determine the residues
primarily responsible for the binding of CPQPRPLC to
VEGFR-1 and to NRP-1. Typically, low-affinity peptide-
receptor interactions (i.e., micromolar range) are ob-
served in NMR spectra as average resonances between
free and bound forms; thus, if the binding equilibrium is
in fast exchange regime (i.e., microseconds), the NMR
parameters will reflect the bound state even if an excess
of free peptide is used [19–21]. Therefore, we performed
binding experiments with a large molar excess of
CPQPRPLC peptide to determine chemical shift
changes from 1D-1H-NMR at 25ºC between the syn-
thetic peptide and the recombinant receptors, VEGFR-
1 or NRP-1, in solution. Given the multiple conformers
and consequent overlapping of peaks, we placed em-
phasis on the analysis of the amide resonances. When
CPQPRPLC was incubated with either VEGFR-1 orNRP-1, only the peptide resonance lines were ob-
served; moreover, resonance lines of residues interact-
ing with each receptor were shifted relative to the
spectrum of CPQPRPLC alone (Figures 2 and see Figure
S1 in the Supplemental Data available with this article
online). Different binding attributes were noted for
each peptide-receptor interaction: VEGFR-1 induced
chemical shift changes in CPQPRPLC resonance lines
corresponding to Arg5 and Leu7 residues (Figure 2A).
Notably, all resonance lines corresponding to these res-
idues changed position. These data indicate that Arg5
and Leu7 are the two key residues involved in the bind-
ing of the CPQPRPLC to VEGFR-1. In addition to Arg5
and Leu7, NRP-1 induced chemical shift changes in res-
onance lines corresponding to Gln3 and Cys1/8 and,
again, several resonances corresponding to the amide
hydrogen of the same residue shifted (Figure 2B). The
fact that different bands corresponding to the same res-
idue changed position upon receptor binding suggests
that CPQPRPLC binding is most likely independent of
a unique peptide conformation, since the timescale of
binding and of the exchange processes are more than
two orders of magnitude different. Two different time-
scales occur during the binding of CPQPRPLC to the
VEGF receptors. The first one is the conformational ex-
change among the different CPQPRPLC conformers.
Because such conformational exchange results in dif-
ferent spin systems (more then one resonance for the
same residue), this timescale is in the tens of millisec-
onds or slower. The second timescale is that associated
with the binding of the peptide to both VEGFR-1 and
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1077Figure2. IdentificationofSpecificCPQPRPLC
Residues Interacting with VEGF Receptors
Amide region of the one-dimensional 1H-
NMR spectra of CPQPRPLC free (red lines)
and in the presence of the indicated receptor
(blue lines) are shown; CPQPRPLC peptide
concentration were 140 mM (A), 280 mM (B),
and 140 mM (C); black lines represent the
spectra of the receptors alone under identical
experimental conditions. In each case, ar-
rows indicate resonances that shifted in the
presence of the receptor. Receptor concen-
trations were: 2 mM of VEGFR-1 (A), 1 mM of
NRP-1 (B), and 2 mM of ephrin-B2 (EphB2) (C).NRP-1 receptors. In this case, the timescale is in a fast
exchange regime (most likely in the microsecond range),
resulting in single resonances and line shifts when in the
presence of large excess of ligands (peptides). Particu-
larly, in the case of CPQPRPLC, several resonances cor-
responding to the amide hydrogen of the same residue
shifted upon binding to both VEGFR-1 and NRP-1, indi-
cating that more than one conformer of the peptide inter-
act with the receptors. Our conclusions, however, do not
imply that there is more then one conformation of the
peptide in the bound state. In contrast, an unrelated
membrane receptor, Ephrin-B2 (EphB2), used as a nega-
tive control did not induce detectable chemical shift
changes in CPQPRPLC resonance lines (Figure 2C).
Taken together, these data indicate that the interaction
between CPQPRPLC and its corresponding VEGF re-
ceptors (1) is not dependent on a unique conformation
of the peptide, and (2) it is most likely mediated by the
residues Arg5 and Leu7. Given that the motif RPL con-
tains both of these residues within CPQPRPLC, we
next set out to determine whether this motif would rep-
resent a minimal peptide binding site for receptor
interaction.
Deconstruction of CPQPRPLC into Overlapping
Tripeptide Motifs Reveals the Structural Basis
for the Peptide-Receptor Interaction
We next used small CPQPRPLC-derived motifs to cir-
cumvent the ambiguities preventing a full analysis of
side-chain interactions and to resolve the possible roles
of Gln3 and Pro6 residues in differentiating ligand-receptor binding of CPQPRPLC to NRP-1 versus
VEGFR-1. Toward that goal, we designed, synthesized,
and analyzed the binding of two overlapping tripeptide
motifs, Gln-Pro-Arg (QPR) and RPL to VEGFR-1 and to
NRP-1. We hypothesized that the motif RPL might suf-
fice for mediating an interaction with either NRP-1 or
VEGFR-1; RPL analysis would also allow us to evalu-
ate the role of Pro6 in differentiating the binding of
CPQPRPLC to NRP-1 versus VEGFR-1. TOCSY and
NOESY experiments were carried out and the resonan-
ces of each tripeptide were assigned either free in solu-
tion or in the presence of each individual receptor (Table
S1). Side-chain chemical shift changes were observed
with both receptors for the motif RPL. Indeed, all reso-
nances in RPL and QPR were analyzed unambiguously
in the presence of VEGFR-1 or NRP-1. The interaction
of RPL with VEGFR-1 or NRP-1 caused chemical shift
changes of amide and side-chain hydrogen atoms of
Arg1 and Leu3 of RPL (Figure 3 and Table 1). In the
case of VEGFR-1, no such changes associated with
the Pro hydrogen atoms were detected. These experi-
ments show that Arg and Leu are the primary residues
that interact with both receptors. However, the interac-
tion of RPL with NRP-1 also involves the participation of
the Pro residue side chain, as evidenced by the 8.8 Hz
chemical shift of Pro.HB hydrogen and the 4.4 Hz chem-
ical shift change of Pro.HG2 (Figure 3 and Table 1). In
contrast, no changes of this magnitude were detected
for the motif QPR, except for a much smaller (2.2 Hz)
shift of Arg3 amide resonance in the presence of NRP-1
(Figure S3), making it unlikely that the motif QPR
Chemistry & Biology
1078Figure 3. Chemical Shift Changes Induced on the Arg-Pro-Leu Motif by Binding to VEGFR-1 and to NRP-1
Two-dimensional TOCSY spectra of Arg-Pro-Leu (800 mM) alone (black) or in the presence of VEGF receptors (red) are shown. Either 2 mM
VEGFR1 (A) or 1 mM NRP-1 (B) were used. Chemical shift changes are indicated. Asterisks point to the lack of detectable chemical shift
changes in the hydrogen atoms of the Pro residue in the presence of VEGFR-1 (upper right, [A]) relative to the 8.8 Hz chemical shift change
observed in the presence of NRP-1 (middle panel, [B]).interacts with NRP-1. Together, these results show that
the motif RPL mediates the interaction to both VEGF re-
ceptors within CPQPRPLC, but the Pro6 residue partic-
ipates only in the binding to NRP-1. Of note, receptor-
ligand interactions are dose-dependent and, in our
case, the NMR parameter (chemical shift changes)
should vary with the peptide concentration. If the fast
exchange regime is reached, chemical shift perturba-
tions should become smaller with increasing concentra-
tions of the peptide. In the case of CPQPRPLC peptide,
we observed little effect of the peptide concentration
upon the chemical shift changes (Figure S1). However,
due to the narrow range of molar concentrations used(60–280 mM) in the experimental design (in order to
avoid peptide oligomerization), no conclusions could
be reached. It is also relevant that peptide oligomers
by themselves may induce changes in the peptide lines,
making it sometimes difficult to distinguish from the
changes induced by receptor binding. This was not
a concern for the smaller motifs (RPL and QPR), since
they could be used in a wider molar concentration range
of (40–800 mM) without noticeable oligomerization. In
the case of the RPL motif, we did observe a clear con-
centration-dependent effect upon the chemical shift
changes (Figure S2). The observed parameter, chemical
shift perturbation, did not go back to zero but, as
Arg-Pro-Leu Is a VEGF Receptor-Binding Motif
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of free peptide. Similar experiments performed with the
noninteractive QPR motif showed no effect upon the
resonance lines (Figure S3).
Finally, to confirm that the Pro6 residue of
CPQPRPLC is not necessary for VEGFR-1 binding (as
it is for NRP-1), we used another NMR-based screening
method: the involvement of the RPL side-chain interac-
tion with VEGFR-1 was analyzed by determining longi-
tudinal relaxation time (T1) changes. It is established
that T1 varies depending on differences in the effective
correlation time, which is affected by the molecule tum-
bling rates, local dynamics, and cross-relaxation [21]; as
a result, upon peptide-receptor binding, distinct tum-
bling rates between the free and bound peptides are in-
duced (by the large difference in molecular weights
between the free peptide and the corresponding recep-
tor). However, the close proximity of residue side chains
to the receptor also changes T1, allowing the mapping
Table 1. Chemical Shift Changes for the RPL Interaction
with VEGFR-1 or NRP-1
Residues
Db (RPLfree 2 RPLbound)
VEGFR-1 (Hz)
Db (RPLfree 2 RPLbound)
NRP-1 (Hz)
Arg.HA 30 99
Arg.HB 14 46
Arg.HG 2.5 6.6
Arg.HD 3.0 6.6
Pro.HB 0.0 8.8
Pro.HG1 0.0 2.0
Pro.HG2 0.0 4.4
Leu.HN 12 11
Leu.HA 0.0 0.0
Leu.HB 0.0 0.0
Leu.HG 0.0 NDa
Leu.HD1 1.3 2.2
Leu.HD2 1.1 2.2
Differences in chemical shift change were determined in free RPL
(800 mM) and in the presence of VEGFR-1 (2 mM) or NRP-1 (1 mM)
and calculated from 2D-TOCSY. Pro.HA was not determined due
to overlap with water. Labile resonances (Arg.HN, HE, and HH) were
not detected due to fast solvent exchange.
a ND, not determined due to overlapping of peaks.of atoms directly involved in the interaction. T1 was
measured with a large molar excess of RPL in the pres-
ence of VEGFR-1. Individual T1 values and differences in
T1 between the free and bound peptides (DT1) were de-
termined (Table 2) and used for mapping (Figure 4). DT1
values were greater for hydrogen atoms in the Arg and
Leu side chains that either had decreased local motion,
or underwent cross-relaxation with the receptor, or
both. No changes in T1 were observed for Pro hydrogen
atoms. These longitudinal relaxation data are consistent
with the chemical shift mapping results (Figure 4) and
indicate that Leu methyl groups are involved in the
VEGFR-1 interaction. These data further support the
contention that the Pro residue of CPQPRPLC is not re-
quired for the interaction with VEGFR-1.
Discussion
An application of phage display screenings is to map
functional protein interacting sites that may serve as
leads for rational drug design. Over the past few years,
we have identified peptide ligands for biochemical
Table 2. Individual T1 Values and Differences between Free
and Bound RPL
Hydrogen
RPL Bound,
ms (SEM)
RPL Free,
ms (SEM)
DT1
a, ms
(SEM)
Arg.HB 455 (15.6) 379 (7.80) 76.0 (23.4)b
Arg.HG 653 (50.7) 549 (20.9) 104 (71.6)
Arg.HD 560 (39.8) 536 (17.2) 24.0 (57.0)
Pro.HB 671 (30.9) 679 (55.9) 8.00 (86.8)
Pro.HG2 680 (25.2) 666 (26.9) 14.0 (52.1)
Leu.HN 459 (11.9) 519 (18.9) 260.0 (30.8)b
Leu.HB 724 (34.0) 590 (27.8) 134 (61.8)b
Leu.HB 514 (9.00) 450 (19.2) 64.0 (28.2)b
Leu.HD 899 (67.4) 630 (4.30) 269 (71.7)b
Leu.HD 752 (61.7) 668 (8.64) 84 (70.3)
Longitudinal relaxation changes (DT1) of RPL peptide hydrogen, free
or in the presence of VEGFR-1. Leu.HA, Arg.HA, and Pro.HG1 were
not determined due to receptor overlapping. Pro.HA was not deter-
mined due to overlap with water.
aDT1 represents difference between bound and free states.
bDT1 greater than 2-fold SEM.Figure 4. Representation of the Atoms within the Motif Arg-Pro-Leu Affected by Receptor Binding to VEGFR-1 or NRP-1
Hydrogen atoms displaying changes in chemical shift or cross-relaxation time (T1) caused by the presence of each receptor are indicated in red.
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1080markers of angiogenic blood vessels, including motifs
binding to cell adhesion molecules [23], proteoglycans
[24], membrane-bound proteases [25, 26], and growth
factor receptors [17, 27]. By screening phage display li-
braries on VEGF-stimulated human endothelial cells, we
have discovered the VEGF-like sequence CPQPRPLC;
we have also shown that this cyclic peptide binds spe-
cifically to VEGFR-1 and to NRP-1 [17]. In this work, we
used NMR to gain mechanistic insight into the structural
attributes of this VEGF receptor-ligand interaction.
We initially analyzed the structural behavior of
CPQPRPLC by 1D-1H-NMR. We found that the peptide
has many conformations, regardless of chemical envi-
ronment (aqueous and organic solvents) or temperature
(from 0ºC to 45ºC). Such structural variability is most
likely secondary to the cis-/trans-isomerization of either
the disulfide bond or the three Pro residues (or both).
Thus, while cyclic peptides are often referred to as
‘‘conformationally constrained,’’ these results illustrate
that—in the absence of structural data—this assump-
tion must be made with caution.
Because of the structural diversity of CPQPRPLC, we
used chemical shift change analysis of the backbone
hydrogen atoms to identify the key residues mediating
the interaction between the VEGF-like peptide and its
VEGF receptors. We found that the residues Arg5 and
Leu7 are critical to the binding to both VEGF receptors
studied. These findings indicate that, regardless of the
intrinsic conformational variability of the peptide, the
binding mechanism is not dependent on a unique con-
formation of the peptide, and suggest that residues
within the motif RPL are central for interactions with
both VEGF receptors. However, if this is so, why would
the IC50 of the synthetic peptide CPQPRPLC for
CPQPRPLC-phage binding to NRP-1 be 100-fold higher
[17] than that for binding to VEGFR-1? To address this
question, we analyzed the interaction of two
CPQPRPLC-derived overlapping tripeptides (QPR and
RPL) with the NRP-1 and VEGFR-1. Essentially, the multi-
conformational nature of the CPQPRPLC peptide cre-
ated several ambiguities in its 1H-NMR spectrum,
which prevented a more detailed analysis of the binding
of the peptide to its corresponding VEGF receptors.
Thus, deconstruction of the peptide CPQPRPLC into
two linear tripeptide motifs was the approach used to
unequivocally show that the tripeptide RPL is indeed
a receptor binding motif, and to fully understand the in-
volvement of each residue in the ligand binding pro-
cess. In particular, we show that the Pro residue
within the RPL motif (Pro6) participates in binding to
NRP-1 but not to VEGFR-1; thus, we propose that the
involvement of Pro6 strengthens the interaction of the
peptide with NRP-1 and induces changes in the back-
bone of CPQPRPLC. These data are consistent with
the larger chemical shift changes observed upon bind-
ing of CPQPRPLC (or RPL) to NRP-1, and may also ex-
plain the chemical shift changes in the residues Gln3
and Cys1/8 of CPQPRPLC during its interaction with
NRP-1.
Keeping in mind that CPQPRPLC was originally iden-
tified as a sequence with similarity to human VEGF-B
isoforms [17], we next compared the protein sequences
encoded by VEGF-B genes from different species. Arg
and Leu residues are conserved cross-species fromrodents to humans, but the Pro residue is not. Specifi-
cally, the Pro residue within the motif RPL is not present
in mice (Arg-Ile-Leu) or rats (Arg-Thr-Leu). Whether the
presence of Pro in this binding site represents an evolu-
tionary gain-of-function remains an open question;
however, one might speculate that Ile or Thr side chains
may interact with NRP-1 through their methyl or ethyl
groups, perhaps compensating for the absence of
a Pro ring. Although the binding of human VEGF-B to
NRP-1 has been documented [18], no information is
as yet available on whether rodent VEGF-B binds to
NRP-1, and if so, with what relative affinity compared
to human VEGF-B. Thus, at this point, the functional sig-
nificance of this finding, while provocative, remains un-
known. However, given that the structure of the heparin
binding domain of VEGF has been solved [28], we mod-
eled the location and receptor accessibility of RPL in the
native VEGF-B molecule (Figure 5A). Analysis of this
molecular model suggests that the motif RPL belongs
to a distinct binding site, outside of the heparin binding
pocket. Of note, eight charged residues (Arg and Lys)
are conserved and may form the basic groove responsi-
ble for heparin binding interactions (Figures 5B and 5C).
This model is consistent with RPL being exposed and
accessible for ligand-receptor binding to NRP-1 and
to VEGFR-1.
In summary, the work presented here establishes
CPQPRPLC as a bona fide ligand peptide to VEGF re-
ceptors. Despite its conformational variability, we deter-
mined that the tripeptide RPL is a critical motif for
receptor binding to NRP-1 and to VEGFR-1, and that
the Pro residue within RPL may account for the differ-
ence observed in binding efficiency to either receptor.
Since drugs that interfere with VEGF pathways have
shown great promise in clinical trials [1–3, 29, 30], pep-
tidomimetics based on these structural insights may
prove useful for rational drug design.
Significance
In theory, phage display and NMR spectroscopy are
complementary technologies to study protein-protein
interactions. However, while conceptually appealing,
serial integration of phage display to NMR has been
hampered by technical challenges (such as, for exam-
ple, the possibility of multiple conformations arising
from a small peptide ligand). Recently, it became clear
that angiogenesis and neuronal development share
molecular mechanisms for specification, differentia-
tion, and patterning formation. Given that VEGF and
its receptors participate in both systems, understand-
ing such ligand-receptor interactions is essential for
the design of VEGF-targeted therapies. Here, as a
proof-of-concept, we used NMR to determine the
structural basis for the differential binding of the pep-
tide CPQPRPLC (selected from a random phage dis-
play library) to its corresponding VEGF receptors.
We analyzed chemical shift changes induced by each
receptor upon the peptide resonances to pinpoint the
key residues responsible for the interaction with
VEGFR-1 and NRP-1. We showed that the tripeptide
motif Arg-Pro-Leu contained within the peptide is suf-
ficient for binding to both receptors, but that Pro6 is
a differential residue that participates only in binding
Arg-Pro-Leu Is a VEGF Receptor-Binding Motif
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VEGF-B167
(A) Ribbon model of the VEGF-B167 heparin binding domain (HBD).
Side-chain residues of the tripeptide Arg-Pro-Leu within the native
VEGF-B167 molecule are represented in red.
(B) Color-coded sequence alignment of human HBD of both VEGF-
B167 and VEGF165: basic residues (Arg or Lys; red) and Cys (orange)
are indicated; the motif Arg-Pro-Leu is highlighted.
(C) Solvent-accessible molecular interface of the VEGF-B167 HBD
model, color-coded to represent electrostatic surface potential:
red, 210 kT; white, 0 kT; and blue, 10 kT. The two views are related
by a 180º rotation around the vertical axis. Yellow indicates the Arg-
Pro-Leu motif. Asterisks represent conserved Arg and Lys resi-
dues. Moreover, all but a single residue are in a favorable region
of the Rammachandran plot; however, the exception, Lys 2, is con-
tained within the very flexible N-terminal region (residues 1–9), as
determined by 15N heteronuclear NOE of the VEGF165 HBD [28].to NRP-1. Thus, the work presented here not only de-
fines Arg-Pro-Leu as a new VEGF receptor binding mo-
tif, but also illustrates how the screening of phage
display peptide libraries and NMR-based technology
can synergize to translate targeting peptide-protein in-
teractions into potential drug delivery tools.
Experimental Procedures
Reagents
Synthetic peptides were generated by Merrifield synthesis to over
95% purity in solid-phase F-MOC (AnaSpec, San Jose, CA). A stan-
dard cyclization protocol was used: exposure to air followed by
cysteine oxidation in ammonium bicarbonate buffer, pH 8. The cycli-
zation and the absence of disulfide-bonded oligomers of
CPQPRPLC were confirmed by mass spectrometry. Further confir-
mation was obtained by reduction and re-formation of the disulfide
bond under controlled conditions. The postrefolding NMR spectrum
was found to be identical to the original spectrum. Peptides were
solubilized in phosphate-buffered saline (PBS) buffer (136 mM
NaCl, 2 mM KCl, 8 mM Na2HPO4, and 1 mM KH2PO4) at pH 7.2
and 10% D2O (99.9%; Isotec, Inc., Miamisburg, OH) for lock purpo-
ses. Experiments were performed in aqueous solution (PBS) unless
otherwise specified; when indicated, additional peptide spectra
were also obtained by increasing concentrations of the organic sol-
vents DMSO (from 0% to 100%) or TFE (from 0% to 60%) in water.
The recombinant receptors VEGFR-1, NRP-1, and EphB2 were pur-
chased from R&D Systems (Minneapolis, MN).
NMR Spectroscopy
NMR experiments were generated on a 600 MHz spectrometer
(Bruker Avance DRX). Chemical shift assignment was accomplished
by using CPQPRPLC (1 mM), RPL (500 mM), and QPR (400 mM) in
PBS (Table S1). One-dimensional spectra were acquired at temper-
atures ranging from 0ºC to 45ºC and were collected with 4096 data
points in F2, with 256 transients. NOESY spectra [31] were acquired
by setting a 200 ms mixing time. Spectra were collected with 400
data points in F1 and 4096 data points in F2, with 80 transients. Wa-
ter suppression was achieved by using the WATERGATE technique
[32]. TOCSY spectra (spin-lock time, 80 ms) were acquired by using
the MLEV-17 pulse sequence [33]. The spectrum was collected with
400 data points in F1 and 4096 data points in F2, with 32 transients.
These experiments were performed at 5ºC.
Analysis of Peptide-Receptor Interactions
A series of one-dimensional 1H-NMR spectra of peptides in the
presence of the VEGF receptors or control proteins was obtained
at 25ºC. The recombinant receptors used in this work (VEGFR-1
and NRP-1) were obtained as fusion proteins to the Fc portion of
the human IgG1 domain Pro100-Lys330. Thus, to ensure that any ob-
served chemical shift changes were specific to the receptor binding
domain (and not to the Fc portion), experiments were repeated un-
der the same conditions by using an unrelated membrane receptor
(EphB2) containing the same fusion protein domain. Unless other-
wise specified, EphB2 served as a negative control receptor be-
cause it is a membrane bound vascular receptor with a similar
molecular weight. Receptor concentrations used were 2 mM for
VEGFR-1, 1 mM for NRP-1, and 2 mM for EphB2. Synthetic peptides
were used in increasing concentrations, from 10 to 800 mM. Pilot ex-
periments revealed that the three synthetic peptides were in their re-
spective monomeric states under the experimental conditions used.
Specifically, the 1H-NMR spectra with increasing concentration of
each individual peptide were analyzed and no significant band shifts
were observed (up to 1 mM). Only in the case of CPQPRPLC were
very small shifts observed (above 400 mM), but they did not prevent
the correct assignment of the peptide. To further minimize the pos-
sibility of peptide oligo-/multimerization, we kept the concentration
of CPQPRPLC under 400 mM in experiments on binding to VEGFR-1
and to NRP-1. For refinement of the analysis of peptide-receptor in-
teraction, TOCSY and NOESY were performed by using 2 mM
VEGFR-1, 1 mM NRP-1, and 800 mM of each peptide. One-dimen-
sional spectra were collected with 4096 data points in F2, with 16
to 10240 transients. Sodium 2,2-dimethyl-2-silapentane-5-sufonate
Chemistry & Biology
1082(DSS) (50–100 mM) served as a reference standard for precise spec-
tra overlapping and comparison.
Longitudinal Relaxation Time Measurements
T1 experiments were performed by inversion-recovery [22] using
RPL (400 mM) in the presence and absence of VEGFR-1 (10 mM).
Spectra were collected with 8192 data points in F2, with 1024 scans.
T1 relaxation times in the pulse sequence varied from 100 ms to 4 s
(n5 11 points). The intensity of each peak in the spectrum was mea-
sured and plotted as a function of the T1 relaxation time.
Molecular Modeling
Homology modeling was done by fitting the primary sequence of the
human VEGF-B167 C terminus (residues 112–167; GenBank no.
AAL79000) to the three-dimensional structure of VEGF (http://
www.rcsb.org/pdb/; PDB accession codes 2VGH and 1VGH; [27]).
Swiss-Model [34], a homology modeling server Web interface
(http://www.expasy.ch/swissmod/), was used for the structural fit-
ting. Refinements of the model, such as the search for side-chain ro-
tamers, the reconstruction of loops, and the energy minimization,
were done through Swiss-PdbViewer (SPDBV) [34].
Supplemental Data
Supplemental Figures S1–S3 and Table S1 are available online at
http://www.chembiol.com/cgi/content/full/12/10/1075/DC1/.
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